We thus employed a systemic approach, whereby we treated a syngeneic orthotopic model of pancreatic cancer with the arginase inhibitor CB-1158 and found it to sensitize PDA to anti-PD1 immune checkpoint blockade. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.